Primus In News
Precision oncology gains ground as India clears targeted cancer therapies
25-12-2025
Nilaya Varma, Group CEO and Co-Founder,Primus Partners, highlights that the approvals represent a major step toward integrating outcome-based precision medicine into routine cancer care, with combination immunotherapies improving treatment outcomes for patient groups that previously had limited options.
Explore Related Insights
- GNSS-based barrierless tolling to reduce 5 million tons of carbon emissions annually: Primus Partner & Think Infra
- Airport lounge access through cards getting tougher: Factors you must know to avoid last-minute shock
- Primus Partners appoints Vinay Singh as Managing Director to drive US expansion
- EV race gets tough for TaMo
